Five-year SENOMAC trial results show omitting completion axillary dissection preserves survival and significantly reduces arm morbidity, says Jana de Boniface, MD, PhD.
Jana de Boniface, MD
Advertisement
Jana de Boniface, MD, is a general surgeon specializing in oncoplastic breast surgery at Karolinska Institutet.
Articles by Jana de Boniface, MD
SENOMAC at ASCO 2026 shows skipping completion ALND in select breast cancer keeps survival high and cuts lymphedema, boosting quality of life.
Advertisement
Latest Updated Articles
Dr de Boniface on Encouraging SENOMAC Trial DataMay 30th 2026
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
AUA/SUO Issue 2026 Update to Non–Muscle-Invasive Bladder Cancer Guideline
2
Dr Pant Discusses Next Steps in Daraxonrasib Development for Pancreatic Cancer
3
Tarlatamab Plus Durvalumab Improves Survival in First-Line ES-SCLC
4
FDA Approves Camizestrant Plus CDK4/6 Inhibitor for ESR1-Mutant Breast Cancer
5